<scp>CDK4/6</scp> inhibitor palbociclib overcomes acquired resistance to third‐generation <scp>EGFR</scp> inhibitor osimertinib in <scp>non‐small</scp> cell lung cancer (<scp>NSCLC</scp>)

Abstract

An osimertinib acquired resistance cell line (H1975 OR) was successfully established. The expression of cell cycle related genes was altered in H1975OR. The expression of CDK4 and the phosphorylation of Rb, the downstream molecule of CDK4/6, was increased in H1975OR cells. The combination of CDK4/6 inhibitor palbociclib and osimertinib could overcome the acquired resistance of osimertinib.